Ignite Creation Date:
2025-12-25 @ 3:24 AM
Ignite Modification Date:
2025-12-26 @ 2:04 AM
Study NCT ID:
NCT05732805
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-02-27
First Post:
2023-02-08
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
Sponsor:
Biocad
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-08-02
Start Date Type:
ACTUAL
Primary Completion Date:
2024-06-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-07
Completion Date Type:
ESTIMATED
First Submit Date:
2023-02-08
First Submit QC Date:
None
Study First Post Date:
2023-02-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-02-25
Last Update Post Date:
2025-02-27
Last Update Post Date Type:
ACTUAL